WO1997020566A1 - Compositions, containing bismuth, for the prevention and treatment of gastrointestinal disorders - Google Patents
Compositions, containing bismuth, for the prevention and treatment of gastrointestinal disorders Download PDFInfo
- Publication number
- WO1997020566A1 WO1997020566A1 PCT/US1996/018653 US9618653W WO9720566A1 WO 1997020566 A1 WO1997020566 A1 WO 1997020566A1 US 9618653 W US9618653 W US 9618653W WO 9720566 A1 WO9720566 A1 WO 9720566A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bismuth
- milligrams
- use according
- treatment
- per day
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/245—Bismuth; Compounds thereof
Definitions
- Id- Treatment of helminth infections has had modest success due to the complexity of the parasitic life cycles of the organisms i.e., egg, first-stage larva, second-stage larva, third-stage larva, free-form, etc.
- an increasing display of resistance to commonly used antihelminthic agents further hinders the likelihood of successful treatment of helminth infections. Therefore, the need for effective antihelminthic therapies continues to grow.
- an object of the present invention is to provide a safe and effective method of preventing and/or treating gastrointestinal disorders caused or mediated by intestinal helminths.
- a further object of the invention is to provide such a method comprising the administration of bismuth.
- the present invention relates to a method for treatment of a human or lower animal subject having a gastrointestinal disorder caused or mediated by one or more intestinal helminths comprising administering to the subject from about 50 milligrams to about 5000 milligrams of bismuth, per day, for from about 1 to 56 days.
- the present invention also relates to a method for prevention in a human or lower animal of a gastrointestinal disorder caused or mediated by one or more intestinal helminths comprising administering to the subject from about 50 milligrams to about 5000 milligrams of bismuth, per day, for from about 1 to 28 days.
- the methods of the present invention comprise the prevention and/or treatment of gastrointestinal disorder caused or mediated by one or more intestinal helminths. Such gastrointestinal disorders are prevented and/or treated by the administration of bismuth.
- the components of the present invention are more fully defined below.
- gastrointestinal disorder encompasses any infection, disease or other disorder of body, typically of the upper and/or lower gastrointestinal tract, caused or mediated by one or more intestinal helminths.
- Such disorders include one or more of the following conditions: diarrhea- abdominal pain and/or cramping, epigastric fullness, constipation, blood and/or mucus present in feces, fever, vomiting, gastroenteritis, weight loss, anemia, malaise, pallor, anal pruritus, and any other condition commonly associated with infection by intestinal helminths.
- Severe infections may even result in dangerous migrations of infection to ectopic sites such as the liver, lungs, etc. or even death.
- gastrointestinal disorder also includes any condition commonly associated with intestinal helminths in immunocompromised subjects and children, including but not limited to bloody diarrhea, extreme constipation, irritability, extreme pruritus, wasting, listlessness, bowel obstruction, and retardation of development.
- Intestinal Helminths are examples of condition commonly associated with intestinal helminths in immunocompromised subjects and children, including but not limited to bloody diarrhea, extreme constipation, irritability, extreme pruritus, wasting, listlessness, bowel obstruction, and retardation of development.
- Intestinal helminths are multi-cellular parasites which have been implicated in intestinal disease.
- intestinal helminths refers to helminths of the following medically important groups: Nematodes, Trematodes, and Cestodes. These organisms are fully described in Zinsser Microbiology. 20th Edition, 1 195-1215, (1992) and Manual of Clinical Microbiology. Sixth Edition, 1141-1144, and 1229-1243, (1995), both of which are incorporated herein by reference.
- Nematodes include Trichinella spiralis, Enterobius ver- micularis (pinworm), Ascaris lumbricoides, Trichuris trichiura (whipworm), Capillaria philippinensis, Ancylcolostoma duodenale (common hookworm), Necator amehcanus (American hookworm), and Trichostrongylus (species such as Strongyloides stercoralis (threadworm).
- Trematodes include Fasciolopsis buski, Heterophyes heterophyes, Metagoniumus yokogawai, and Nanophyetus salmincola.
- Cestodes include Diphyllobothrium latum, Tae ia saginata, T enia solium, and Hymenolepis nana.
- Preferred intestinal helminths are Enterobius vermicular is, Ancylostoma duodenale, Trichuris trichiura, Fasciolopsis buski, Trichostrongylus species, Taenia saginata, and combinations thereof.
- Most preferred parasitic protozoa are Enterobius vermicularis, Ancylostoma duodenale, Trichuris trichiura, and combinations thereof.
- Diagnosis of gastrointestinal disorders caused or mediated by intestinal helminths may be accomplished by any method commonly used in the medical community. Such methods are fully described in Zinsser Microbiology, and Manual of Clinical Microbiology, as referenced above. BismutJ
- the methods of treatment and/or prevention in the present invention involve administration of bismuth.
- the quantity of bismuth is by weight of elemental bismuth.
- bismuth may be administered in an amount of from about 50 milligrams to about 5000 milligrams, and preferably from about 50 milligrams to about 2500 milligrams, per day, for from about 1 to about 56 days, preferably for from about 2 to about 28 days, and most preferably for from about 7 to about 21 days.
- bismuth may be administered in an amount of from about 50 milligrams to about 5000 milligrams, and preferably from about 50 milligrams to about 2500 milligrams, per day, for from about 1 to about 21 days, and preferably for from about 1 to about 14 days.
- bismuth may be administered prior to potential exposure to intestinal helminths. Such administration of bismuth may vary depending on the likelihood of intestinal helminth exposure and condition of the subject and may be commenced at any time deemed beneficial by the medical community including from about 1 to about 7 days, from about 2 to about 5 days, and from about 3 to about 4 days, prior to potential exposure.
- bismuth includes bis ⁇ muth in the form of a pharmaceutically-acceptable salt, bismuth in the form of an organic or other complex which contains bismuth as an active ingredient, and mixtures thereof.
- organic complexes include 2,2'-spirobi[l,3,2- benzodoxabismole].
- bismuth is administered in the present methods as a pharmaceutically-acceptable salt.
- Such bismuth salts include bismuth aluminate, bismuth subcarbonate, bismuth subcitrate, bismuth citrate, tripotassium dicitrato bismuthate, bismuth subgalate, bismuth subnitrate, bismuth tartrate, bismuth subsalicylate, and mixtures thereof.
- Bismuth citrate, bismuth subcitrate, tripotassium dicitrato bismuthate, bismuth tartrate, bismuth subsalicylate, and mixtures thereof are preferred bismuth salts for use in this invention.
- the bismuth useful herein may be administered alone, or in combination with other pharmaceutically-acceptable components in a bismuth-containing composition.
- compositions containing bismuth salts are commercially available.
- Such compositions include DeNol, containing tripotassium dicitrato bismuthate (by Brocades); Bislumina, containing bismuth aluminate (by Mazuelos); Roter, containing bismuth subnitrate (by Roterpharma); Devrom®, containing bismuth subgallate (by The Parthenon Co., Inc.); and Pepto-Bismol®, containing bismuth subsalicylate (by The Procter & Gamble Company).
- administering refers to any method which, in sound medical practice delivers the compounds or compositions used in this invention to the subject to be treated in such a manner so as to be effective in the treatment ofthe gastrointestinal disorder.
- the bismuth is administered orally.
- tripotassium dicitrate bismuthate tartrate, bismuth citrate, and bismuth subnitrate are substituted, respectively, for bismuth subsalicylate, with substantially similar results.
- Analysis of fecal specimens reveals the presence of barrel shaped eggs (20-50 m in size, golden brown in color, and having a transparent prominence or polar plug at each end), characteristic of Trichuris trichiura.
- the infection is diagnosed and treated by orally administering approximately 400 milligrams of bismuth in the form of bismuth subcitrate ("DeNol" sold by Brocades), in four equal doses daily for about 28 days. Thereafter, fecal samples from the subject are analyzed again, finding no trace of helminthic infection.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL12474296A IL124742A0 (en) | 1995-12-07 | 1996-11-22 | Compositions comprising a bismuth compound for the prevention and treatment of gastrointestinal disorders |
CA002239422A CA2239422C (en) | 1995-12-07 | 1996-11-22 | Compositions, containing bismuth, for the prevention and treatment of gastrointestinal disorders |
BR9611913A BR9611913A (en) | 1995-12-07 | 1996-11-22 | Compositions containing bismuth for the prevention and treatment of gastrointestinal disorders |
EP96940569A EP0865285B1 (en) | 1995-12-07 | 1996-11-22 | Compositions, containing bismuth, for the prevention and treatment of gastrointestinal disorders |
AT96940569T ATE211914T1 (en) | 1995-12-07 | 1996-11-22 | COMPOSITIONS CONTAINING BISMUTH FOR THE PREVENTION AND TREATMENT OF GASTROINTESTINAL DISEASES |
DE69618617T DE69618617T2 (en) | 1995-12-07 | 1996-11-22 | COMPOSITIONS CONTAINING WISMUTH FOR THE PREVENTION AND TREATMENT OF GASTROINTESTINAL COMPLAINTS |
NO982633A NO982633L (en) | 1995-12-07 | 1998-06-08 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56885395A | 1995-12-07 | 1995-12-07 | |
US08/568,853 | 1995-12-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997020566A1 true WO1997020566A1 (en) | 1997-06-12 |
Family
ID=24273009
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/018653 WO1997020566A1 (en) | 1995-12-07 | 1996-11-22 | Compositions, containing bismuth, for the prevention and treatment of gastrointestinal disorders |
Country Status (13)
Country | Link |
---|---|
US (1) | US5932564A (en) |
EP (1) | EP0865285B1 (en) |
AT (1) | ATE211914T1 (en) |
BR (1) | BR9611913A (en) |
CA (1) | CA2239422C (en) |
CO (1) | CO4761071A1 (en) |
DE (1) | DE69618617T2 (en) |
IL (1) | IL124742A0 (en) |
NO (1) | NO982633L (en) |
PE (1) | PE37198A1 (en) |
TR (1) | TR199801043T2 (en) |
TW (1) | TW421595B (en) |
WO (1) | WO1997020566A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0206626A2 (en) * | 1985-06-13 | 1986-12-30 | Barry James Dr. Marshall | Use of Bismuth for the manufacture of a medicament for the treatment of gastrointestinal disorders induced by Campylobacter polyridis |
WO1995022521A1 (en) * | 1994-02-22 | 1995-08-24 | Asahi Kasei Kogyo Kabushiki Kaisha | Aminoalkylcyclopropane derivative |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR962163A (en) * | 1950-06-02 | |||
US4049817A (en) * | 1972-08-14 | 1977-09-20 | Sandoz Ltd. | Synergistic compositions |
US4514421A (en) * | 1979-08-30 | 1985-04-30 | Herschler R J | Dietary and pharmaceutical uses of methylsulfonylmethane and compositions comprising it |
US5256684A (en) * | 1985-06-13 | 1993-10-26 | The Procter & Gamble Company | Methods and compositions for the treatment of gastrointestinal disorders |
JPS63174926A (en) * | 1987-01-09 | 1988-07-19 | Nitto Kasei Kk | Anticoccidial agent for domestic fowl |
US5221664A (en) * | 1990-04-23 | 1993-06-22 | Magainin Pharmaaceuticals Inc. | Composition and treatment with biologically active peptides and toxic cations |
KR100193933B1 (en) * | 1990-07-20 | 1999-06-15 | 에밀리오 캠포레시, 존 페르구손 | Water-soluble complexes of bismuth and polyacrylates, preparation methods thereof, and pharmaceutical compositions for treating ulcerative colitis containing the complexes or other bismuth salts |
-
1996
- 1996-11-22 AT AT96940569T patent/ATE211914T1/en not_active IP Right Cessation
- 1996-11-22 WO PCT/US1996/018653 patent/WO1997020566A1/en active IP Right Grant
- 1996-11-22 TR TR1998/01043T patent/TR199801043T2/en unknown
- 1996-11-22 CA CA002239422A patent/CA2239422C/en not_active Expired - Fee Related
- 1996-11-22 EP EP96940569A patent/EP0865285B1/en not_active Expired - Lifetime
- 1996-11-22 DE DE69618617T patent/DE69618617T2/en not_active Expired - Fee Related
- 1996-11-22 IL IL12474296A patent/IL124742A0/en unknown
- 1996-11-22 BR BR9611913A patent/BR9611913A/en not_active Application Discontinuation
- 1996-12-04 CO CO96063578A patent/CO4761071A1/en unknown
- 1996-12-09 PE PE1996000885A patent/PE37198A1/en not_active Application Discontinuation
- 1996-12-26 TW TW085116052A patent/TW421595B/en not_active IP Right Cessation
-
1997
- 1997-01-08 US US08/780,526 patent/US5932564A/en not_active Expired - Fee Related
-
1998
- 1998-06-08 NO NO982633A patent/NO982633L/no not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0206626A2 (en) * | 1985-06-13 | 1986-12-30 | Barry James Dr. Marshall | Use of Bismuth for the manufacture of a medicament for the treatment of gastrointestinal disorders induced by Campylobacter polyridis |
WO1995022521A1 (en) * | 1994-02-22 | 1995-08-24 | Asahi Kasei Kogyo Kabushiki Kaisha | Aminoalkylcyclopropane derivative |
Non-Patent Citations (1)
Title |
---|
STEFFEN R.: "Worldwide efficacy of bismuth subsalicylate in the treatment of travelers' diarrhea", REV. INFECT. DIS., 1990, 12/SUPPL. 1 (S80-S86), USA, XP000602908 * |
Also Published As
Publication number | Publication date |
---|---|
CO4761071A1 (en) | 1999-04-27 |
US5932564A (en) | 1999-08-03 |
ATE211914T1 (en) | 2002-02-15 |
DE69618617D1 (en) | 2002-02-21 |
EP0865285B1 (en) | 2002-01-16 |
NO982633L (en) | 1998-08-04 |
BR9611913A (en) | 1999-03-02 |
CA2239422C (en) | 2003-03-11 |
TW421595B (en) | 2001-02-11 |
CA2239422A1 (en) | 1997-06-12 |
IL124742A0 (en) | 1999-01-26 |
DE69618617T2 (en) | 2002-09-19 |
EP0865285A1 (en) | 1998-09-23 |
MX9804579A (en) | 1998-10-31 |
TR199801043T2 (en) | 1998-09-21 |
PE37198A1 (en) | 1998-08-27 |
NO982633D0 (en) | 1998-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5601848A (en) | Methods for the treatment of gastrointestinal disorders | |
Podesta et al. | Treatment of pruritus of primary biliary cirrhosis with rifampin | |
EP0462631B1 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
US5256684A (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
Whitaker et al. | Edathamil calcium disodium (Versenate) diagnostic test for lead poisoning | |
Hadden et al. | Diagnosis and treatment of human fascioliasis | |
EP0865285B1 (en) | Compositions, containing bismuth, for the prevention and treatment of gastrointestinal disorders | |
US4959384A (en) | Use of nitrofurantoin for the treatment and prophylaxis of gastrointestinal disorders | |
US6051604A (en) | Methods and compositions for the prevention and treatment of gastrointestinal disorders | |
Schillinger et al. | The toxic effect of intravenous application of the trypanocide isometamidium (Samorin®) | |
Ali | Prevention of ammonia‐induced gastric lesions in rats by natural honey | |
MXPA98004579A (en) | Compositions containing bismute for the prevention and treatment of gastrointestine disorders | |
Afifi et al. | Amoxycillin in treatment of typhoid fever in patients with haematological contraindications to chloramphenicol. | |
Lane | The clinical aspects of poisoning by inorganic lead compounds | |
JPH11504939A (en) | Bismuth-containing composition for treatment and prevention of gastrointestinal disorders | |
JPH11504940A (en) | Bismuth and one or more antimicrobial-containing compositions for the treatment and prevention of gastrointestinal disorders | |
RAMSEY et al. | THE RELATIVE EFFICIENCY OF THE DIFFERENT MERCURIAL PREPARATIONS IN THE TREATMENT OF CONGENITAL SYPHILIS IN INFANTS AND CHILDREN: AS DETERMINED BY A QUANTITATIVE ANALYSIS OF THE MERCURY ELIMINATED IN THE URINE | |
Stastny | Cardiac involvement in lyme disease: Manifestations and management: Olson LJ, Okafor EC, Clements IP. Mayo Clin Proc. 1986; 61: 745–749 | |
Goodwin | Antibiotics in Helicobacter pylori Treatment | |
DAHMS et al. | Campylobacter pylori Gastritis and Peptic Ulcer in Children-Reply | |
JPH09188624A (en) | Medicine for treating hepatic encephalopathy or medicine for preventing hepatic encephalopathy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): BR CA IL MX NO TR |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2239422 Country of ref document: CA Ref document number: 2239422 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1998/004579 Country of ref document: MX Ref document number: 1998/01043 Country of ref document: TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996940569 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1996940569 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1996940569 Country of ref document: EP |